




PHARMACEUTICAL 2021

G1 Therapeutics Inc.
Rank 153 of 402





RealRate

PHARMACEUTICAL 2021

G1 Therapeutics Inc.
Rank 153 of 402



The relative strengths and weaknesses of G1 Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of G1 Therapeutics Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 43% points. The greatest weakness of G1 Therapeutics Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 147%, being 100% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	216,392
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	23,443
Liabilities, Non-Current	7,865
Other Assets	9,678
Other Compr. Net Income	0
Other Expenses	1,410
Other Liabilities	19,893
Other Net Income	-1,368
Other Revenues	45,285
Property and Equipment	2,482
Research and Development	73,271
Selling, General and Administrative Expense	68,490

Output Variable	Value in 1000 USD
Assets	228,552
Liabilities	51,201
Expenses	143,171
Revenues	45,285
Stockholders Equity	177,351
Net Income	-99,254
Comprehensive Net Income	-99,254
Economic Capital Ratio	147%